Analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to post earnings of ($0.65) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for PTC Therapeutics’ earnings. The lowest EPS estimate is ($0.78) and the highest is ($0.51). PTC Therapeutics reported earnings of ($0.46) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 41.3%. The business is scheduled to announce its next quarterly earnings results on Thursday, February 27th.
According to Zacks, analysts expect that PTC Therapeutics will report full-year earnings of ($3.78) per share for the current financial year, with EPS estimates ranging from ($3.87) to ($3.61). For the next financial year, analysts expect that the firm will post earnings of ($1.47) per share, with EPS estimates ranging from ($1.64) to ($1.36). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover PTC Therapeutics.
PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.15). The business had revenue of $71.40 million for the quarter, compared to analyst estimates of $72.03 million. PTC Therapeutics had a negative net margin of 74.86% and a negative return on equity of 31.92%. The firm’s revenue for the quarter was up 33.2% on a year-over-year basis. During the same period in the prior year, the company earned ($1.06) earnings per share.
In other PTC Therapeutics news, CEO Stuart Walter Peltz sold 22,463 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $49.43, for a total transaction of $1,110,346.09. 7.00% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of PTC Therapeutics by 15.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,596 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 474 shares in the last quarter. Sicart Associates LLC grew its stake in PTC Therapeutics by 6.7% in the third quarter. Sicart Associates LLC now owns 8,725 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 550 shares in the last quarter. Strs Ohio grew its stake in PTC Therapeutics by 7.3% in the second quarter. Strs Ohio now owns 14,700 shares of the biopharmaceutical company’s stock valued at $661,000 after purchasing an additional 1,000 shares in the last quarter. Rhumbline Advisers increased its position in PTC Therapeutics by 1.3% in the 3rd quarter. Rhumbline Advisers now owns 80,822 shares of the biopharmaceutical company’s stock worth $2,733,000 after purchasing an additional 1,057 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in PTC Therapeutics by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 89,240 shares of the biopharmaceutical company’s stock worth $3,018,000 after purchasing an additional 1,066 shares during the last quarter. 99.31% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ PTCT traded up $0.53 during trading on Monday, hitting $48.25. The company had a trading volume of 900,276 shares, compared to its average volume of 791,263. PTC Therapeutics has a 52 week low of $27.53 and a 52 week high of $50.96. The business’s 50-day moving average is $44.00 and its 200 day moving average is $42.32. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.40 and a quick ratio of 4.30.
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.